VERTEX PHARMACEUTICALS INC / MA Insider Trading for November 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for November 2017.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 149.80 | 206 | 30,859 | 106,011 | 106.2 K to 106 K (-0.19 %) |
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 147.71 | 100 | 14,771 | 106,217 | 106.3 K to 106.2 K (-0.09 %) |
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 147.29 | 23 | 3,388 | 16,634 | 16.7 K to 16.6 K (-0.14 %) |
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 147.29 | 7 | 1,031 | 40,888 | 40.9 K to 40.9 K (-0.02 %) |
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 147.29 | 83 | 12,225 | 50,710 | 50.8 K to 50.7 K (-0.16 %) |
Nov 17 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 147.29 | 221 | 32,551 | 41,952 | 42.2 K to 42 K (-0.52 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Option Exercise | M | 77.31 | 4,250 | 328,568 | 4,250 | |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Option Exercise | M | 91.05 | 2,155 | 196,213 | 19,397 | |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 150.00 | 4,250 | 637,500 | 40,888 | 45.1 K to 40.9 K (-9.42 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Buy | M | 77.31 | 4,250 | 328,568 | 45,138 | 40.9 K to 45.1 K (+10.39 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Sell | S | 150.00 | 2,155 | 323,250 | 40,888 | 43 K to 40.9 K (-5.01 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, COO | Buy | M | 91.05 | 2,155 | 196,213 | 43,043 | 40.9 K to 43 K (+5.27 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 86.52 | 2,330 | 201,592 | 30,289 | |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 149.50 | 2,330 | 348,335 | 28,809 | 31.1 K to 28.8 K (-7.48 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 86.52 | 2,330 | 201,592 | 31,139 | 28.8 K to 31.1 K (+8.09 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 77.31 | 4,250 | 328,568 | 4,250 | |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 148.17 | 4,250 | 629,723 | 41,952 | 46.2 K to 42 K (-9.20 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 77.31 | 4,250 | 328,568 | 46,202 | 42 K to 46.2 K (+10.13 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Option Exercise | M | 93.51 | 7,073 | 661,396 | 0 | |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Sell | S | 143.05 | 7,073 | 1,011,793 | 3,953 | 11 K to 4 K (-64.15 %) |
Nov 07 2017 | VRTX | VERTEX PHARMACEUTI ... | Bhatia Sangeeta N. | Director | Buy | M | 93.51 | 7,073 | 661,396 | 11,026 | 4 K to 11 K (+178.93 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 109.14 | 3,594 | 392,249 | 17,969 | |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 91.05 | 1,796 | 163,526 | 16,164 | |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 144.69 | 3,594 | 520,016 | 54,424 | 58 K to 54.4 K (-6.19 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 109.14 | 3,594 | 392,249 | 58,018 | 54.4 K to 58 K (+6.60 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 145.89 | 300 | 43,767 | 54,424 | 54.7 K to 54.4 K (-0.55 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 144.89 | 1,096 | 158,799 | 54,724 | 55.8 K to 54.7 K (-1.96 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 143.54 | 400 | 57,416 | 55,820 | 56.2 K to 55.8 K (-0.71 %) |
Nov 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 91.05 | 1,796 | 163,526 | 56,220 | 54.4 K to 56.2 K (+3.30 %) |